

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Dalteparin sodium
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 23, 2022
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Leo Pharma | Sunnybrook Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2021
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Leo Pharma | Sunnybrook Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.
Product Name : Innohep
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2015
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Dalteparin sodium
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 09, 2014
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : Christine Ribic
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of Tinzaparin for Anticoagulation in Hemodialysis
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2013
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : Christine Ribic
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Details : Bemiparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thrombosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2013
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Use Of Fragmin In Hemodialysis
Details : Fragmin (Dalteparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Fragmin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2013
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nadroparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2013
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Dalteparin sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Aarhus University Hospital | Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fetal Growth Retardation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2011
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Aarhus University Hospital | Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thromboembolism.
Product Name : Innohep
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2010
Lead Product(s) : Dalteparin sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
